Compared with other EGFR TKIs, osimertinib seems to have a higher risk for cardiac events including decreased LVEF and prolongation of QTc. In an interesting analysis utilizing the FDA Adverse Events Reporting System (FAERS), investigators found that, when compared with all drugs reported in this da...